key: cord-1003828-2vqxp9n1
authors: Shuwa, Halima A.; Shaw, Tovah N.; Knight, Sean B.; Wemyss, Kelly; McClure, Flora A.; Pearmain, Laurence; Prise, Ian; Jagger, Christopher; Morgan, David.J.; Khan, Saba; Brand, Oliver; Mann, Elizabeth R.; Ustianowski, Andrew; Bakerly, Nawar Diar; Dark, Paul; Brightling, Christopher E.; Brij, Seema; Felton, Timothy; Simpson, Angela; Grainger, John R.; Hussell, Tracy; Konkel, Joanne E.; Menon, Madhvi
title: Alterations in T and B cell function persist in convalescent COVID-19 patients
date: 2021-03-31
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.03.013
sha: 4870c5642a6efb0d4f8fb07ab230b07059924251
doc_id: 1003828
cord_uid: 2vqxp9n1

Background Emerging studies indicate that some COVID-19 patients suffer from persistent symptoms including breathlessness and chronic fatigue; however the long-term immune response in these patients presently remains ill-defined. Methods Here we describe the phenotypic and functional characteristics of B and T cells in hospitalised COVID-19 patients during acute disease and at 3-6 months of convalescence. Findings We report that the alterations in B cell subsets observed in acute COVID-19 patients were largely recovered in convalescent patients. In contrast, T cells from convalescent patients displayed continued alterations with persistence of a cytotoxic programme evident in CD8+ T cells as well as elevated production of type-1 cytokines and IL-17. Interestingly, B cells from patients with acute COVID-19 displayed an IL-6/IL-10 cytokine imbalance in response to toll-like receptor activation, skewed towards a pro-inflammatory phenotype. Whereas the frequency of IL-6+ B cells was restored in convalescent patients irrespective of clinical outcome, recovery of IL-10+ B cells was associated with resolution of lung pathology. Conclusions Our data detail lymphocyte alterations in previously hospitalized COVID-19 patients up to 6 months following hospital discharge and identify 3 subgroups of convalescent patients based on distinct lymphocyte phenotypes, with one subgroup associated with poorer clinical outcome. We propose that alterations in B and T cell function following hospitalisation with COVID-19 could impact longer term immunity and contribute to some persistent symptoms observed in convalescent COVID-19 patients. Funding Provided by UKRI, Lister Institute of Preventative Medicine, The Wellcome Trust, The Kennedy Trust for Rheumatology Research and 3M Global Giving.

The coronavirus disease 2019 pandemic, caused by the emergence of a novel coronavirus strain, has resulted, at this time, in more than 106 million infections and 2.3 million deaths worldwide. Infection with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has a plethora of consequences ranging from mild flu-like symptoms to life-threatening and fatal acute respiratory distress syndrome 1, 2 . In all cases, the pathology is underpinned by not merely the virus itself but also an aberrant inflammatory host immune response. Research efforts detailing immune parameters in patients with acute COVID-19 have significantly improved our understanding of the disease, highlighting profound alterations in the innate and adaptive immune compartments [3] [4] [5] [6] [7] . Lymphopenia, as well as altered lymphocyte function, have been reported to correlate with disease severity 1, 8 , indicating key roles for T and B cells in COVID-19 pathology.

Emerging evidence suggests that COVID-19 patients can develop a spectrum of long-lasting symptoms, including chronic fatigue, myalgia, brain fog, fibrotic lung disease and pulmonary vascular disease [9] [10] [11] . Although the immune response in acute COVID-19 patients has been well characterized, long-term consequences of SARS-CoV-2 infection remain poorly understood.

Since SARS-CoV-2 specific lymphocytes are likely critical for long-term protection against SARS-CoV-2 following disease resolution, it is pivotal to understand their contribution to acute disease, recovery, as well as long-lasting post-COVID-19 symptoms. Indeed ground-breaking studies are demonstrating antigen-specific responses to this virus can persist for several months post-infection [12] [13] [14] [15] . However, given the vast numbers of previously infected individuals across the globe, it is also vital to understand the impact of COVID-19 on the phenotype and functional potential of all lymphocytes, not just those reactive to SARS-CoV2. This will allow for better understanding of the long-term impacts of being hospitalised with COVID-19 on effective immunity. Indeed, long-term follow-up of Ebola patients has outlined immune dysfunction J o u r n a l P r e -p r o o f 5 persisting for up to 2 years of convalescence 16 . Following much shorter periods of convalescence, individuals hospitalised with influenza infection have been shown to exhibit continued elevation in CD8 + T cell activation and proliferation 17 . Given the prolonged and profound immune dysregulation seen during acute SARS-CoV2 infection, there is a compelling need to determine whether these alterations translate into longer-term immune alterations and subsequent dysfunction in convalescent individuals.

Here, we examined lymphocytes in COVID-19 patients during hospitalization and in convalescent patients over 6 months following hospital discharge. Specifically, we examined lymphocyte characteristics in PBMCs from blood samples taken from COVID-19 patients within 7 days of hospitalization, at hospital discharge and at up to 6 months post hospital discharge.

Samples were collected as part of the Coronavirus Immune Response and Clinical Outcomes (CIRCO) study based at four hospitals in Greater Manchester 5 . Examination of these samples allowed us to ascertain changes to lymphocytes during acute disease and upon convalescence in COVID-19 patients. We identify key alterations in B cell populations in acute COVID-19 patients with severe disease, which indicate imbalances within the B cell compartment could contribute to COVID-19 disease severity. Specifically, we demonstrate that in severe COVID-19 patients there was a loss of transitional B cells and an expansion of double negative memory B cells. Moreover, B cells exhibited altered functionality with increased production of IL-6 during acute disease, which was restored in convalescent patients. Intriguingly, B cell production of IL-10 was higher in convalescent patients with good clinical outcomes compared to patients with poor outcomes. In line with this, we also report changes within the CD4 + T cell compartment of acute COVID-19 patients, specifically increases in T follicular helper cells (Tfh) that were recovered in convalescent patients. In contrast, we outline persistent alterations in the functional potential of CD8 + T cells, with T cells from convalescent patients exhibiting elevated expression of a cytotoxic programme and production of type-I cytokines. These data describe alterations to J o u r n a l P r e -p r o o f 6 lymphocytes, detailing previously undescribed imbalances within the B cell compartment associated with the severity of acute disease and alterations in lymphocyte potential that persist for at least 6 months of convalescence. Further, compiling B and T immune parameters from convalescent patients identified 3 patient subgroups, defined by i) increased cytotoxic T cells and T cell type-I cytokine production, ii) high proportions of memory, IgA + and IgG + B cells and iii) highest expression of trafficking molecules and increased proportions of naïve B and T cells.

It is noteworthy that the convalescent group defined by the highest proportions of cytotoxic CD8 + T cells and type-I cytokine production was enriched in patients with a poorer outcome at follow-up, defined by abnormal chest X-Ray. Our study provides a deeper understanding of lymphocyte responses over the course of COVID-19 and into recovery, highlighting persistent alterations in lymphocyte functionality in convalescent COVID-19 patients up to 6 months following hospital discharge.

Between 29 th March and 15 th July 2020 we recruited patients during their in-patient stay for COVID-19, who had clinical and lymphocyte data available and who were recruited within 7 days of admission. 'Convalescent' patients were recruited between 14 th July and October 2020 from out-patient clinical follow-up for COVID-19. Convalescent patients are therefore classified as previously hospitalised COVID-19 patients who are clinically stable and have been discharged from any further inpatient care. Convalescent patients were sampled between 53-180 days of convalescence. For convalescent patients sampled twice during their convalescence they were initially sampled between 67-180 days of convalescence and then sampled between 20-113 days later (with the latest second sample being taken at day 201 following discharge). For convalescent disease samples, one patient was excluded due to a significant co-existent pathology during in-patient admission for COVID-19; all others were J o u r n a l P r e -p r o o f 7 included in the analysis. The median age and overall gender proportions were similar between acute and convalescent groups. There was a larger proportion of severe patients within the convalescent group, reflecting that patients with more severe disease were prioritised for limited 'face to face' appointments in participating trusts. The clinical characteristics of all patients recruited to the study are summarised in Supplemental Tables 1-2 .

In agreement with previously published studies 5,6 , we report significantly reduced circulating B cell frequencies in severe COVID-19 patients, that were normalized in convalescent patients ( Fig. 1A) . Further, increased Ki-67 expression (indicative of proliferation) in hospitalized patients was not observed in convalescent patients ( Fig. 1B and Supplemental Fig. 1A) . When characterizing B cell subsets based on expression of CD27 and IgD, we saw an expansion of CD27 -IgDdouble negative (DN) memory B cells in severe COVID-19 patients that was still present in convalescent patients (Fig. 1C, D) . No differences in unswitched memory (USM), switched memory (SM), or naïve B cells were observed between the patient groups and controls. Further classification of B cell subsets into transitional (CD24 hi CD38 hi ) and mature (CD24 int CD38 int ) B cells revealed a significant reduction in transitional B cells in patients with severe COVID-19 that was restored in convalescent patients (Fig. 1E, F) . A t-distributed stochastic neighbour embedding (tSNE) representation of the data highlights proportions of subsets in acute and convalescent COVID-19 patients (Fig. 1G) . Importantly, CD27 hi CD38 hi plasmablasts were the only B cell subset expanded in all COVID-19 patients irrespective of severity, yet proportions were restored in convalescent patients ( Fig. 1H and Supplemental Combined, these data highlight alterations in B cell subsets during severe acute COVID-19 which are largely restored upon convalescence.

Previous studies have detailed CD8 + and CD4 + T cell activation in COVID-19 patients 6,21-23 .

Here, we show that convalescent patients exhibited elevated proportions of T effector memory cells positive for CD45RA (TEMRA; CD45RA + CCR7 -) ( Fig. 2A-C 6 . CD8 + T cells from acute COVID-19 patients exhibit robust expression of a cytotoxic programme, with increases in perforin, granzyme and CD107a expression in unstimulated cells ( Fig. 2E-G) . Induction of this programme was still evident in convalescent patients, whose CD8 + T cells exhibited increased expression of both perforin and granzyme (Fig. 2E, F) . However, the proportions of CD107a + and Ki-67 + GranzymeB + CD8 + T cells in convalescent patients were reduced compared to those with acute COVID-19 suggesting cytotoxic CD8 + T cells in convalescent patients were no longer actively proliferating or degranulating (Fig. 2G) . Showing the same pattern, longitudinal tracking of individual patients from their acute time-point into convalescence showed unchanged perforin and granzyme B expression in CD8 + T cells (Fig. 2H) , but reduced Ki-67 + , CD107a + and Ki-67 + GranzymeB + CD8 + T cells at convalescent compared to acute time-points (Fig. 2I) . We also J o u r n a l P r e -p r o o f 9 noted a persistence of this cytotoxic profile in CD8 + T cells in a small subset of convalescent patients examined beyond 6 months after hospital discharge. Obtaining a second convalescent sample from the same patient at a later time-point of convalescence, demonstrated persistence of this cytotoxic programme beyond 6 months (Supplemental Fig. 1L ).

In contrast to these phenotypic changes persisting in the CD8 + T cell compartment up to, and potentially beyond, 6 months of convalescence, alterations noted in acute disease in CD4 + T cells were normalized in convalescent patients. There were no significant changes in regulatory T cells (Tregs) across the disease trajectory (Fig. 2J) , but during acute disease there was an expansion in T follicular helper cells (Tfh), defined as CD4 + CXCR5 + PD-1 + ICOS + (Fig.   2K ). While an increase in Tfh has been previously reported in acute COVID-19 patients 6,24-26 , we show it was reduced in convalescent patients (Fig. 2K) . This decrease in Tfh in convalescent patients occurred following hospital discharge (Fig. 2L) and could be identified when following the same patient from acute disease into convalescence (Fig. 2M) . Combined these data demonstrate changes in the functional potential of CD8 + T cells up to 6 months following hospital discharge, outlining continued expression of a cytotoxic programme.

Lymphopenia is a well-established hallmark of COVID-19 patients 1 that are mostly restored upon convalescence. Reduced CXCR3 and CXCR5 expression could reflect reduced homing of lymphocytes into lymph nodes and follicles, which have been reported to contribute to immune dysfunction in other infections, such as advanced HIV [27] [28] [29] . Altogether, here we identify changes in chemokine receptor expression during acute disease that are recovered upon convalescence.

To understand the impact of COVID-19 on the potential of lymphocytes to make distinct cytokines, we stimulated PBMCs with phorbol myristrate acetate (PMA) and Ionomycin and examined cytokine production by T cells (see Supplemental Fig. 3A for example staining).

Unlike previously published studies probing antigen specificity of T cells in COVID-19 patients 14,30 , we more broadly assessed the potential of all T cells in COVID-19 patients to secrete cytokines. This approach allowed us to assess the impact of COVID-19 hospitalisation on any subsequent immune response, as opposed to the development of SARS-CoV2-specific memory. IL-10 + CD4 + T cells were expanded in acute COVID-19 patients, but this was not observed in convalescent patients (Fig. 3A) . Normalisation of IL-10 production from CD4 + T cells did not occur during hospitalisation, as a decrease in IL-10 + CD4 + T cells was not evident J o u r n a l P r e -p r o o f 11 upon discharge (Supplemental Fig. 3B ). As previously reported to occur in response to anti-CD3 and anti-CD28 stimulation 31 , PMA and Ionomycin stimulation resulted in increased IL-17 + CD4 + T cells in COVID-19 patients (Fig. 3B) . Remarkably, enhanced IL-17 + CD4 + T cells persisted into convalescence. We next queried whether elevated production of IL-17 during convalescence was associated with any specific clinical phenotypes. Increased IL-17 + CD4 + T cells in convalescent patients were seen irrespective of whether patients were stratified by presentation of normal or abnormal chest X-rays (Fig. 3B) , reporting versus not reporting increased fatigue or based upon initial disease severity (Supplemental Fig. 3C ).

Despite increased IL-10 + and IL-17 + CD4 + T cells, neither CD4 + or CD8 + T cells from acute COVID-19 patients exhibited altered proportions of cells staining positive for the canonical Th1 cytokines IFNγ or TNFα (Fig. 3C, D) . Although a previous study has reported that high proportions of antigen-specific IFNγ T cells are associated with reduced disease severity 26 , our observation is in line with other studies demonstrating total peripheral T cell populations exhibit no enhanced production of these cytokines despite on-going disease 6, 32 , and irrespective of acute disease severity (Supplemental Fig. 3D, E) . In stark contrast, both CD4 + and CD8 + T cells from convalescent COVID-19 patients exhibited enhanced production of type-I cytokines ( Fig. 3C, D) . This increase in cytokine production was not evident at hospital discharge (Supplemental Fig. 3F, G) . Increased type-I cytokines occurred when stratifying convalescent patients by presentation of normal or abnormal chest X-rays (Fig. 3C, D) and those reporting increased fatigue. Of note no significant increase in IFNγ + CD4 + T cells was seen when stratifying patients for fatigue (Supplemental Fig. 3H ). Increased production of type-I cytokines in convalescent patients was associated with COVID-19 disease severity, apart from for IFNγ + CD4 + T cells, as patients who had moderate and severe disease showed significant increases in cytokine positive cells relative to controls (Fig. 3E, F) . As such, the increases seen in total convalescent patients could be due to increased proportions of patients that exhibited J o u r n a l P r e -p r o o f 12 severe disease. However, comparing proportions of cytokine-positive cells in severe patients at acute and convalescent time-points still showed an elevation in cytokine producing T cells, apart from for TNFα + CD8 + T cells (Supplemental Fig. 3I, J) . More importantly, longitudinal data tracking the same patient across their acute and convalescent disease time-points also showed increased production of these type-I cytokines (except for IFNγ + TNFα + CD4 + T cells) (Fig. 3G,H) .

In a small subset of patients we also obtained a second convalescent sample after 6 months from hospital discharge. In this small group we noted unchanged proportions of cytokine positive T cells, suggesting persistence of elevated cytokine production beyond 6 months (Supplemental Fig. 3K,L) . These data fit with previous studies showing IFNγ + and TNFα + SARS-CoV-2 specific-T cells in convalescent patients 14, 30, 33 but further outline that altered cytokine potential is a general feature of all T cells during COVID-19 convalescence.

Next, in order to assess cytokine production by B cells, we stimulated PBMCs from COVID-19 patients with CpGB (a TLR9 agonist) for 48 hours and measured cytokine expression by flow cytometry. We observed a significant expansion of IL-6 + B cells in acute COVID-19 patients and a trend toward a decrease in IL-10 + B cells; suggesting an imbalance in B cells towards a more pro-inflammatory phenotype ( Fig. 3I and Supplemental Fig. 4A-D) . The frequency of IL-6 + B cells was restored in convalescent patients, and was not impacted by presentation of normal or abnormal chest X-rays (Fig. 3I ) or fatigue (Supplemental Fig. 4D) .

Interestingly, B cell production of IL-10 was higher in convalescent patients with a good clinical outcome compared to those with a poor outcome. Increased proportions of IL-10 + B cells in convalescent patients with normal chest X-rays compared to those with abnormal chest X-rays Fig. 4E,F) . Longitudinal analysis of individual patients from acute disease into convalescence showed no change in either IL-6 + or TNFα + B cells but did demonstrate a recovery of IL-10 + B cells upon convalescence (Fig. 3J) . Of note, only 1 out of 13 patients whose B cells were followed longitudinally exhibited an abnormal chest X-ray at follow-up.

Combined, these data demonstrate an expansion of IL-6 + B cells during acute disease and reduced proportions of IL-10 + B cells in convalescent patients with poor clinical outcome.

Collectively, our data establish alterations in the lymphocyte compartment that persist up to 6 months post hospital discharge in convalescent patients. In order to further probe lymphocyte changes within convalescent COVID-19 patients, we clustered patients based on T and B cell features. Unsupervised clustering revealed three groups of convalescent patients with distinct compositions of lymphocyte signatures (Fig. 4A) . Group In sum, here we report lymphocyte changes across the COVID-19 disease trajectory into convalescence. Our data demonstrate a high degree of activation of a cytotoxic programme within CD8 + T cells during acute disease as previously reported 3, 5, 34 . We extend these data by showing persistence of this programme within circulating CD8 + T cells up to at least 6 months of convalescence. Whereas previous studies have shown persistence of low frequencies of SARS-CoV2-specific CD8 + T cells with a cytotoxic profile 33 In summary, we report phenotypic and functional alterations to B and T cells across the trajectory of SARS-CoV2 responses from acute disease requiring hospitalisation into convalescence, identifying immune alterations that persist in convalescent COVID-19 patients for up to 6 months. Our study therefore identifies lymphocyte changes in convalescent COVID-19 patients which could have longer term impacts on subsequent anti-pathogen or autoinflammatory responses.

J o u r n a l P r e -p r o o f 16 Our study has limitations, including the reduced number of samples from patients at acute disease (n=58) relative to those during convalescence (n=83), indeed for some parameters only 30 acute samples were examined. Furthermore, disease severity in the acute group did not match that in the convalescent group; the latter contained more severe patients (acute=22.4%; convalescence=49.4%). In addition, only 14 patients were followed longitudinally from acute disease into convalescence, our study would have been significantly enhanced if we could have followed more individual patients. Our study would have been further enhanced were it possible to examine convalescent patients at later time-points, for example 9 months and 1 year. would like to thank the following for technical and scientific discussions; the Lydia Becker

Immunology Consortium, and PHOSP-COVID. 

None to declare. Table 3 ). Where severity of disease changed during admission, the highest disease severity score was selected for classification. Peripheral blood samples were collected within 7 days of hospital admission, at discharge and then at 3-9 months post hospital discharge when patients returned to out-patient clinics.

Supplemental Tables 1-2.

Recruiting healthy individuals from the community for blood sampling during the SARS-CoV-2 outbreak was not possible, and therefore we sampled frontline workers from NHS Trusts and University of Manchester staff with an age range that was similar to our COVID-19 patients (age range 35-71; median age=50.9; 52% males). All healthy controls tested negative for anti-Spike1 receptor binding domain antibodies. Following stimulation cells were washed and stained for flow cytometric analysis.

PBMCs (fresh/thawed/stimulated) were stained with fluorophore conjugated antibodies (see Key

Resource Table) and viability dyes. Samples were acquired on an LSRFortessa cell analyser (Becon Dickinson) and analysed using FlowJo (TreeStar).

T cell and B cell data were scaled using unit variance scaling, clustered and graphed using correlation distance and average linkage on the heatmap tool on ClustVis 42.

Results are presented as individual data points with medians. Normality tests were performed on all datasets. Groups were compared using an unpaired Mann-Whitney test for healthy individuals versus COVID-19 patients, one-way ANOVA with Holm-Sidak post-hoc testing patients, detailing persistent alterations in lymphocyte phenotype up to 6 months following hospital discharge. In this report they identify 3 subgroups of convalescent patients based on distinct lymphocyte signatures, with one subgroup associated with poorer clinical outcome.

The coronavirus disease 2019 (COVID-19) pandemic, caused by a novel coronavirus strain, has resulted in over 100 million infections world-wide. Emerging evidence suggests that some COVID-19 patients suffer persistent symptoms including fatigue, fibrotic lung disease and myalgia, however the long-term immune response in these patients remains ill-defined.

Here, we conducted an observational study examining lymphocyte populations in COVID-19 patients during hospitalization and at up to 6 months of convalescence. We identified a number of lymphocyte alterations that persisted in convalescent patients. Moreover, compilation of lymphocyte parameters in convalescent COVID-19 patients identified 3 distinct patient subgroups, with one subgroup associated with poorer clinical outcome. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Clinical Characteristics of Coronavirus Disease 2019 in China

Comprehensive mapping of immune perturbations associated with severe COVID-19

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Long term respiratory complications of covid-19

Covid-19 and chronic fatigue

Management of post-acute covid-19 in primary care

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

Long-lasting severe immune dysfunction in Ebola virus disease survivors

Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study

Serum IgA, IgM, and IgG responses in COVID-19

Antibody responses to SARS-CoV-2 in patients with COVID-19

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

A dynamic COVID-19 immune signature includes associations with poor prognosis

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

T cell responses in patients with COVID-19

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2. medRxiv. Publ Online

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Decreased CXCR3+ CD8 T Cells in Advanced Human Immunodeficiency Virus Infection Suggest that a Homing Defect Contributes to Cytotoxic T-Lymphocyte Dysfunction

Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus

CXCR5, the Defining Marker for Follicular B Helper T (TFH) Cells. Front Immunol

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Dysregulation of Immune Response in Patients With Coronavirus

SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Antibody response to SARS-CoV-2 -sustained after all?

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma

Regulatory and effector B cells: Friends or foes?

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients

CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation

Human regulatory B cells in health and disease: therapeutic potential

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

This study was funded by the BBSRC (BB/M025977/1 to JEK, BB/S01103X/1 to TNS), by the